Loading…

Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology

Introduction: Because of the increased use of im plantable access systems, the incidence of blood stream and catheter infections associated with these systems has concomitantly increased. Classically, he parin-lock flush solutions were used to prevent thrombosis; more recently, vancomycin was added...

Full description

Saved in:
Bibliographic Details
Published in:Journal of oncology pharmacy practice 1997-03, Vol.3 (1), p.18-23
Main Authors: Vincentelli, J., Braguer, D., Guillet, P., Delorme, J., Carles, G., Perez, R., Duffaud, F., Nicoara, A., Drancourt, M., Favre, R., Crevat, A.
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c202t-649c2f39b60da3009e9f4b1443e6926a4ece0dc5e88bba6a4dd78d67b85854f03
cites cdi_FETCH-LOGICAL-c202t-649c2f39b60da3009e9f4b1443e6926a4ece0dc5e88bba6a4dd78d67b85854f03
container_end_page 23
container_issue 1
container_start_page 18
container_title Journal of oncology pharmacy practice
container_volume 3
creator Vincentelli, J.
Braguer, D.
Guillet, P.
Delorme, J.
Carles, G.
Perez, R.
Duffaud, F.
Nicoara, A.
Drancourt, M.
Favre, R.
Crevat, A.
description Introduction: Because of the increased use of im plantable access systems, the incidence of blood stream and catheter infections associated with these systems has concomitantly increased. Classically, he parin-lock flush solutions were used to prevent thrombosis; more recently, vancomycin was added to the solution to prevent infections caused by Gram- positive bacteria, particularly coagulase-negative Staphylococci. Disorders due to Gram-negative organ isms have now appeared in oncologic patients. We therefore tested the addition of colistin to heparin- vancomycin solutions. Colistin was chosen for its good activity against Gram-negative bacteria (98% susceptibility in our hospital), its good tolerance due to low systemic passage, and its low cost. Methods: We developed formulations contain ing heparin (100 IU/mL) and various concentrations of vancomycin (10-500 μg/mL) and colistin (10-100 μg/mL) in 0.9% NaCl. Each sterile solution was tested for physical and chemical compatibility (spectropho tometry, nuclear magnetic resonance, and pH mea surements) and its antibacterial activity (against ox acillin-resistant Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae exhibiting broad- spectrum betalactamase (BSBL), imipenem-resistant Pseudomonas aeruginosa) for 2 months at 4°C and at room temperature. Results: The most suitable combination of drugs is heparin (100 IU/mL), vancomycin (100 μg/mL), and colistin (100 μg/mL). This flush solution main tains activity when stored at 4°C for up to 1 month. Conclusions: We feel that the combination of heparin, vancomycin, and colistin can be used as a flush solution for indwelling catheters.
doi_str_mv 10.1177/107815529700300103
format article
fullrecord <record><control><sourceid>sage_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1177_107815529700300103</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_107815529700300103</sage_id><sourcerecordid>10.1177_107815529700300103</sourcerecordid><originalsourceid>FETCH-LOGICAL-c202t-649c2f39b60da3009e9f4b1443e6926a4ece0dc5e88bba6a4dd78d67b85854f03</originalsourceid><addsrcrecordid>eNp9kMFKxDAQhoMouK6-gKc8gHUnadokR1lcFQQvCt5Kmia7XdJkSVqhb2-W1ZPgaf4Z_m-Y-RG6JXBPCOcrAlyQqqKSA5QABMoztCCM8wIk_TzPOhuKo-MSXaW0BwDBqVigsAlxmJwa--BxsFhh66a0wym46Xe2MwcVe3-Hv5TXYZj1USvfYR1cn8beYxsi7oeDU35UrTNYaW1SwmlOoxkSzo6QSRe28zW6sMolc_NTl-hj8_i-fi5e355e1g-vhaZAx6JmUlNbyraGTuWHpJGWtYSx0tSS1ooZbaDTlRGibVXuu46LruatqETFLJRLRE97dQwpRWObQ-wHFeeGQHOMrPkbWYZWJyiprWn2YYo-3_gf8Q2QJ24H</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology</title><source>SAGE Deep Backfile 2012</source><creator>Vincentelli, J. ; Braguer, D. ; Guillet, P. ; Delorme, J. ; Carles, G. ; Perez, R. ; Duffaud, F. ; Nicoara, A. ; Drancourt, M. ; Favre, R. ; Crevat, A.</creator><creatorcontrib>Vincentelli, J. ; Braguer, D. ; Guillet, P. ; Delorme, J. ; Carles, G. ; Perez, R. ; Duffaud, F. ; Nicoara, A. ; Drancourt, M. ; Favre, R. ; Crevat, A.</creatorcontrib><description>Introduction: Because of the increased use of im plantable access systems, the incidence of blood stream and catheter infections associated with these systems has concomitantly increased. Classically, he parin-lock flush solutions were used to prevent thrombosis; more recently, vancomycin was added to the solution to prevent infections caused by Gram- positive bacteria, particularly coagulase-negative Staphylococci. Disorders due to Gram-negative organ isms have now appeared in oncologic patients. We therefore tested the addition of colistin to heparin- vancomycin solutions. Colistin was chosen for its good activity against Gram-negative bacteria (98% susceptibility in our hospital), its good tolerance due to low systemic passage, and its low cost. Methods: We developed formulations contain ing heparin (100 IU/mL) and various concentrations of vancomycin (10-500 μg/mL) and colistin (10-100 μg/mL) in 0.9% NaCl. Each sterile solution was tested for physical and chemical compatibility (spectropho tometry, nuclear magnetic resonance, and pH mea surements) and its antibacterial activity (against ox acillin-resistant Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae exhibiting broad- spectrum betalactamase (BSBL), imipenem-resistant Pseudomonas aeruginosa) for 2 months at 4°C and at room temperature. Results: The most suitable combination of drugs is heparin (100 IU/mL), vancomycin (100 μg/mL), and colistin (100 μg/mL). This flush solution main tains activity when stored at 4°C for up to 1 month. Conclusions: We feel that the combination of heparin, vancomycin, and colistin can be used as a flush solution for indwelling catheters.</description><identifier>ISSN: 1078-1552</identifier><identifier>EISSN: 1477-092X</identifier><identifier>DOI: 10.1177/107815529700300103</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><ispartof>Journal of oncology pharmacy practice, 1997-03, Vol.3 (1), p.18-23</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c202t-649c2f39b60da3009e9f4b1443e6926a4ece0dc5e88bba6a4dd78d67b85854f03</citedby><cites>FETCH-LOGICAL-c202t-649c2f39b60da3009e9f4b1443e6926a4ece0dc5e88bba6a4dd78d67b85854f03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/107815529700300103$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/107815529700300103$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21845,27924,27925,45082,45470</link.rule.ids></links><search><creatorcontrib>Vincentelli, J.</creatorcontrib><creatorcontrib>Braguer, D.</creatorcontrib><creatorcontrib>Guillet, P.</creatorcontrib><creatorcontrib>Delorme, J.</creatorcontrib><creatorcontrib>Carles, G.</creatorcontrib><creatorcontrib>Perez, R.</creatorcontrib><creatorcontrib>Duffaud, F.</creatorcontrib><creatorcontrib>Nicoara, A.</creatorcontrib><creatorcontrib>Drancourt, M.</creatorcontrib><creatorcontrib>Favre, R.</creatorcontrib><creatorcontrib>Crevat, A.</creatorcontrib><title>Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology</title><title>Journal of oncology pharmacy practice</title><description>Introduction: Because of the increased use of im plantable access systems, the incidence of blood stream and catheter infections associated with these systems has concomitantly increased. Classically, he parin-lock flush solutions were used to prevent thrombosis; more recently, vancomycin was added to the solution to prevent infections caused by Gram- positive bacteria, particularly coagulase-negative Staphylococci. Disorders due to Gram-negative organ isms have now appeared in oncologic patients. We therefore tested the addition of colistin to heparin- vancomycin solutions. Colistin was chosen for its good activity against Gram-negative bacteria (98% susceptibility in our hospital), its good tolerance due to low systemic passage, and its low cost. Methods: We developed formulations contain ing heparin (100 IU/mL) and various concentrations of vancomycin (10-500 μg/mL) and colistin (10-100 μg/mL) in 0.9% NaCl. Each sterile solution was tested for physical and chemical compatibility (spectropho tometry, nuclear magnetic resonance, and pH mea surements) and its antibacterial activity (against ox acillin-resistant Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae exhibiting broad- spectrum betalactamase (BSBL), imipenem-resistant Pseudomonas aeruginosa) for 2 months at 4°C and at room temperature. Results: The most suitable combination of drugs is heparin (100 IU/mL), vancomycin (100 μg/mL), and colistin (100 μg/mL). This flush solution main tains activity when stored at 4°C for up to 1 month. Conclusions: We feel that the combination of heparin, vancomycin, and colistin can be used as a flush solution for indwelling catheters.</description><issn>1078-1552</issn><issn>1477-092X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><recordid>eNp9kMFKxDAQhoMouK6-gKc8gHUnadokR1lcFQQvCt5Kmia7XdJkSVqhb2-W1ZPgaf4Z_m-Y-RG6JXBPCOcrAlyQqqKSA5QABMoztCCM8wIk_TzPOhuKo-MSXaW0BwDBqVigsAlxmJwa--BxsFhh66a0wym46Xe2MwcVe3-Hv5TXYZj1USvfYR1cn8beYxsi7oeDU35UrTNYaW1SwmlOoxkSzo6QSRe28zW6sMolc_NTl-hj8_i-fi5e355e1g-vhaZAx6JmUlNbyraGTuWHpJGWtYSx0tSS1ooZbaDTlRGibVXuu46LruatqETFLJRLRE97dQwpRWObQ-wHFeeGQHOMrPkbWYZWJyiprWn2YYo-3_gf8Q2QJ24H</recordid><startdate>199703</startdate><enddate>199703</enddate><creator>Vincentelli, J.</creator><creator>Braguer, D.</creator><creator>Guillet, P.</creator><creator>Delorme, J.</creator><creator>Carles, G.</creator><creator>Perez, R.</creator><creator>Duffaud, F.</creator><creator>Nicoara, A.</creator><creator>Drancourt, M.</creator><creator>Favre, R.</creator><creator>Crevat, A.</creator><general>SAGE Publications</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>199703</creationdate><title>Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology</title><author>Vincentelli, J. ; Braguer, D. ; Guillet, P. ; Delorme, J. ; Carles, G. ; Perez, R. ; Duffaud, F. ; Nicoara, A. ; Drancourt, M. ; Favre, R. ; Crevat, A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c202t-649c2f39b60da3009e9f4b1443e6926a4ece0dc5e88bba6a4dd78d67b85854f03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vincentelli, J.</creatorcontrib><creatorcontrib>Braguer, D.</creatorcontrib><creatorcontrib>Guillet, P.</creatorcontrib><creatorcontrib>Delorme, J.</creatorcontrib><creatorcontrib>Carles, G.</creatorcontrib><creatorcontrib>Perez, R.</creatorcontrib><creatorcontrib>Duffaud, F.</creatorcontrib><creatorcontrib>Nicoara, A.</creatorcontrib><creatorcontrib>Drancourt, M.</creatorcontrib><creatorcontrib>Favre, R.</creatorcontrib><creatorcontrib>Crevat, A.</creatorcontrib><collection>CrossRef</collection><jtitle>Journal of oncology pharmacy practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vincentelli, J.</au><au>Braguer, D.</au><au>Guillet, P.</au><au>Delorme, J.</au><au>Carles, G.</au><au>Perez, R.</au><au>Duffaud, F.</au><au>Nicoara, A.</au><au>Drancourt, M.</au><au>Favre, R.</au><au>Crevat, A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology</atitle><jtitle>Journal of oncology pharmacy practice</jtitle><date>1997-03</date><risdate>1997</risdate><volume>3</volume><issue>1</issue><spage>18</spage><epage>23</epage><pages>18-23</pages><issn>1078-1552</issn><eissn>1477-092X</eissn><abstract>Introduction: Because of the increased use of im plantable access systems, the incidence of blood stream and catheter infections associated with these systems has concomitantly increased. Classically, he parin-lock flush solutions were used to prevent thrombosis; more recently, vancomycin was added to the solution to prevent infections caused by Gram- positive bacteria, particularly coagulase-negative Staphylococci. Disorders due to Gram-negative organ isms have now appeared in oncologic patients. We therefore tested the addition of colistin to heparin- vancomycin solutions. Colistin was chosen for its good activity against Gram-negative bacteria (98% susceptibility in our hospital), its good tolerance due to low systemic passage, and its low cost. Methods: We developed formulations contain ing heparin (100 IU/mL) and various concentrations of vancomycin (10-500 μg/mL) and colistin (10-100 μg/mL) in 0.9% NaCl. Each sterile solution was tested for physical and chemical compatibility (spectropho tometry, nuclear magnetic resonance, and pH mea surements) and its antibacterial activity (against ox acillin-resistant Staphylococcus aureus, Enterococcus faecium, Klebsiella pneumoniae exhibiting broad- spectrum betalactamase (BSBL), imipenem-resistant Pseudomonas aeruginosa) for 2 months at 4°C and at room temperature. Results: The most suitable combination of drugs is heparin (100 IU/mL), vancomycin (100 μg/mL), and colistin (100 μg/mL). This flush solution main tains activity when stored at 4°C for up to 1 month. Conclusions: We feel that the combination of heparin, vancomycin, and colistin can be used as a flush solution for indwelling catheters.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><doi>10.1177/107815529700300103</doi><tpages>6</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1078-1552
ispartof Journal of oncology pharmacy practice, 1997-03, Vol.3 (1), p.18-23
issn 1078-1552
1477-092X
language eng
recordid cdi_crossref_primary_10_1177_107815529700300103
source SAGE Deep Backfile 2012
title Formulation of a flush solution of heparin, vancomycin, and colistin for implantable access systems in oncology
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T19%3A37%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-sage_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Formulation%20of%20a%20flush%20solution%20of%20heparin,%20vancomycin,%20and%20colistin%20for%20implantable%20access%20systems%20in%20oncology&rft.jtitle=Journal%20of%20oncology%20pharmacy%20practice&rft.au=Vincentelli,%20J.&rft.date=1997-03&rft.volume=3&rft.issue=1&rft.spage=18&rft.epage=23&rft.pages=18-23&rft.issn=1078-1552&rft.eissn=1477-092X&rft_id=info:doi/10.1177/107815529700300103&rft_dat=%3Csage_cross%3E10.1177_107815529700300103%3C/sage_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c202t-649c2f39b60da3009e9f4b1443e6926a4ece0dc5e88bba6a4dd78d67b85854f03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rft_sage_id=10.1177_107815529700300103&rfr_iscdi=true